Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (21202)	9/8/2006 11:41:25 AM
From: dr.praveen	Respond to of 52153

Thanks Peter. Actually I read them last night. If you compare the efficacy to the current injectables it pales in comparision. No doubt this won't be a monotherapy. It showed a dose response with 0.1 and 0.3mg doses. I want to see how 1) The 0.6mg dose will do(Think results are coming out on sept 26th) 2) Being an Oral MS drug, I want to see the Combo data with B Ifn and other injectables as an add on therapy. Thanks for your abstracts again, Praveen